Browse articles from EyeWorld.org related to dry eye. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves dry eye drop targeting tear evaporation ➤ Topline results from Phase 3 trial of eye drops for DME ➤ Investigational intravitreal gene therapy program introduced for geographic atrophy ➤ Phase 1 study for periocular drug for wet AMD and DME begins ➤ Commercial rights for uveitis treatment acquired ➤ ASCRS news and events
➤ Fast-Track Designation granted for persistent epithelial defect treatment ➤ Study: automated capsulotomy device and white cataracts ➤ Dose escalation complete for Phase 1/2 study evaluating an RP treatment ➤ Companies enter agreement for sustained-release glaucoma treatment ➤ ASCRS news and events
➤ Positive preclinical results for non-viral gene therapy platform ➤ Real-world data confirms efficacy of investigational LHON therapy ➤ Largest genome wide study of photoreceptor cells to date ➤ CDC continues to investigate infectious outbreak associated with artificial tear use ➤ Updates from AAV-based gene therapy program for retinal conditions ➤ ASCRS news and events
➤ NDA submitted for sustained-release travoprost implant ➤ BLA for wet AMD, DME, DR treatment accepted with priority review ➤ Topline results from 12-month safety clinical trial for investigational dry eye drug ➤ Companies collaborate for research on sustained release for investigational GA drug ➤ ASCRS news and events
➤ Alert: eye infections linked to artificial tear ➤ Phase 2 data from research targeting Sjogren’s treatment ➤ First patient dosed in Phase 1 study for epithelial defect treatment ➤ Study compares DMEK tissue preparation techniques ➤ Topline results from oral diabetic retinopathy treatment trial ➤ ASCRS news and events
➤ Bausch + Lomb acquires AcuFocus ➤ Study: novel drug delivery system sees less inflammation with preserved drops ➤ Meibomian gland atrophy common among cataract patients, study finds ➤ mRNA technology investigated for gene therapy to treat blindness ➤ Studies find new bionic vision system offers improved outcomes ➤ ASCRS news and events
The use of autologous blood eye drops continues to be a point of interest in research and as a potential cost-effective alternative to processed hemoderivatives. A recent study published in the journal Clinical Ophthalmology continues to advance the topic.
➤ NDA submitted to FDA for drug that reverses mydriasis ➤ FDA cleared IND application for gene therapy to treat form of Leber congenital amaurosis ➤ FDA approves IND for research to move forward on RP gene therapy ➤ Phase 2 study to treat geographic atrophy begins ➤ Study: Weaning patients off of AMD treatments compared ➤ Possible geographic atrophy treatment explored ➤ ASCRS news and events
➤ FDA approves AI-based diabetic retinopathy screener ➤ FDA accepts NDA for Demodex treatment ➤ Phase 2b results for MGD therapy ➤ Phase 1/2 trial evaluates investigational TED treatment ➤ Phase 1 clinical trial to study synthetic cannabinoid derivative for glaucoma ➤ OCT company rebrands ➤ ASCRS news and events
➤ Topline results from Phase 3 study of atropine for myopia progression ➤ Phase 3 results for novel glaucoma drop ➤ Positive results from two Phase 3 studies for patients with RVO ➤ Phase 3 results for cell therapy treating macular telangiectasia type 2 ➤ Single injection of investigational compound for DME improves BCVA ➤ FDA accepts BLA for ophthalmic bevacizumab ➤ Mobile phone attachment developed for ophthalmic clinical trials ➤ ASCRS news and events